Mometasone Nasal

Preclinical

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Mometasone Nasal is one of 2 therapeutic programs targeting Rhinitis, Allergic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Rhinitis, AllergicRecruiting

Rhinitis, AllergicPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Rhinitis, Allergic

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Approved

1 2

Mometasone Nasal

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Rhinitis, Allergic

NCT06436534

Clinical

Trials by Indication[1]

Rhinitis, Allergic1 trial

A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Preclinical·NCT06436534·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mometasone Nasal. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mometasone Nasal. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Mometasone Nasal

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Rhinitis, Allergic1 trial

References

Drug Info

Quick Facts

Related News